First Tracks Biotherapeutics, Inc.
TRAX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002091349
In the last 90 days, First Tracks Biotherapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 150 institutions reported holding it in 13F filings for Q2 2026, worth $685.8M in total; no superinvestor holds it.
Superinvestors holding TRAX, Q2 2026
No superinvestor reported holding TRAX in Q2 2026.